Skip to main content

Advertisement

Table 1 Patient, disease, and transplant characteristics

From: Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study

Characteristics Donor source  
Father (N = 223) Mother (N = 47) Sibling (N = 91) Child (N = 29) P
Patient age  
 Median (range), years 12 (1–36) 11 (4–30) 27 (4–55) 43 (29–54) 0.000
 ≥ 20 years 61 (27.4%) 14 (29.8%) 72 (79.1%) 29 (100%) 0.000
 < 20 years 162 (72.6%) 33 (70.2%) 19 (20.9%) 0 (0%)  
Patient gender 0.040
 Male 119 (53.4%) 23 (48.9%) 63 (69.2%) 18 (62.1%)  
 Female 104 (46.6%) 24 (51.1%) 28 (30.8%) 11 (37.9%)  
Donor age  
 Median (range), years 41 (24–63) 37 (20–54) 28 (7–53) 16 (10–28) 0.000
 ≥ 40 years 125 (56.1%) 19 (40.4%) 6 (6.6%) 0 (0%) 0.000
 < 40 years 98 (43.9%) 28 (59.6%) 85 (93.4%) 29 (100%)  
Donor gender 0.000
 Male 223 (100%) 0 (0%) 54 (59.3%) 19 (65.5%)  
 Female 0 (0%) 47 (100%) 37 (40.7%) 10 (34.5%)  
Donor-recipient gender 0.000
 Male to male 119 (53.4%) 0 (0%) 40 (44.0%) 11 (37.9%)  
 Female to male 0 (0%) 23 (48.9%) 23 (25.3%) 7 (24.1%)  
 Male to female 104 (46.6%) 0 (0%) 14 (15.4%) 8 (27.6%)  
 Female to female 0 (0%) 24 (51.1%) 14 (15.4%) 3 (10.3%)  
Months from diagnosis to transplant  
 Median (range), months 12 (1–260) 8 (1–144) 12 (1–468) 13 (1–264) 0.374
 < 12 months 108 (48.4%) 28 (59.6%) 43 (47.3%) 11 (37.9%) 0.301
 ≥ 12 months 115 (51.6%) 19 (40.4%) 48 (52.7%) 18 (62.1%)  
Transfusion before transplant  
 RBC, median (range), U 20 (1–600) 17 (0–180) 20 (2–300) 16 (2–160) 0.724
 PLT, median (range), U 13.5 (0–248) 11.5 (0–60) 16 (0–80) 15 (2–120) 0.721
Ferritin  
 Median (range), ng/ml 1701.5 (9–20251) 1801 (189–7434) 1978.5 (23–10550) 1904 (197–8467) 0.633
ECOG score pre-SCT, median (range) 0.406
 0 55 (24.7%) 7 (14.9%) 17 (18.7%) 6 (20.7%)  
 1 121 (54.3%) 26 (55.3%) 57 (62.6%) 19 (65.5%)  
 ≥ 2 47 (21.1%) 14 (29.8%) 17 (18.7%) 4 (13.8%)  
Previous ATG treatment 0.211
 Yes 42 (18.8%) 8 (17.0%) 14 (15.6%) 1 (3.4%)  
 No 181 (81.2%) 39 (83.0%) 77 (84.6%) 28 (96.6%)  
Matched HLA loci at A, B, DR 0.032
 3/6 188 (84.3%) 29 (61.7%) 68 (74.7%) 23 (79.3%)  
 4/6 26 (11.7%) 13 (27.7%) 18 (19.8%) 5 (17.2%)  
 5–6/6 9 (4.0%) 5 (10.6%) 5 (5.5%) 1 (3.4%)  
Donor-recipient ABO match status 0.326
 Match 124 (55.6%) 23 (48.9%) 46 (50.5%) 20 (69.0%)  
 Minor mismatch 47 (21.1%) 14 (29.8%) 15 (16.5%) 4 (13.8%)  
 Major mismatch 40 (17.9%) 8 (17.0%) 20 (22.0%) 3 (10.3%)  
 Bidirectional mismatch 12 (5.4%) 2 (4.3%) 10 (11.0%) 2 (6.9%)  
Number of nucleated cells  
 Median (range), × 108/kg 9.44 (5.07–25.13) 9.18 (6.57–15.29) 9.93 (4.06–18.11) 9.88 (5.82–16.86) 0.628
Number of CD34-positive cells  
 Median (range), × 106/kg 3.12 (0.14–22.47) 2.52 (0.67–10.31) 3.26 (0.57–11.48) 3.48 (0.84–8.72) 0.045
  1. ATG anti-thymocyte globulin, ECOG Eastern Cooperative Oncology Group, PLT platelet, RBC red blood cell, SCT stem cell transplantation.